Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer drug olaparib, potentially expanding its benefits beyond patients with ...

Patients with the most common molecular subtype of advanced breast cancer now have a targeted drug approved specifically for ...

A pair of existing cancer drugs reversed memory loss, reduced tau protein clumps, and curbed neurodegeneration in mouse models of Alzheimer’s disease, according to findings published in Cell on July ...

A drug widely used to treat asthma and allergies may also help fight aggressive cancers, reports a new Northwestern Medicine study that uncovered how tumors hijack common white blood cells to evade ...

The Food and Drug Administration granted accelerated approval on Wednesday for a new drug developed by researchers at the Broad Institute that treats non-small cell lung cancer — the most common type ...

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A common cancer drug has been restructured to make its cancer cell ...

The below is a summary of a story that originally appeared on the Duke Health News website. Immunotherapy has transformed cancer care by helping the immune system recognize and destroy tumors. But new ...

Being able to predict the resistance or sensitivity of a tumor cell to a drug is a key success-factor of cancer precision therapy. But such a prediction is made difficult by the fact that genetic ...

Ratain is the Leon O. Jacobson professor of medicine and director of the Center of Personalized Therapeutics at the University of Chicago and chairman of the Board of the Optimal Cancer Care Alliance.